Skip to main content

Advertisement

Table 3 Baseline parameters and the reduction of body weight or HbA1c in the unchanged treatment group

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Baseline parameters Reduction of body weight Reduction of HbA1c
  Univariate Multivariate p value Univariate Multivariate p value
  r p value   r p value  
Age −0.178 0.307   −0.147 0.401  
Male −0.240 0.165   −0.053 0.764  
BMI 0.502 0.003 0.051 0.406 0.017 0.448
WC 0.294 0.208   0.243 0.302  
Duration of DM −0.162 0.208   −0.052 0.784  
SBP −0.370 0.029 0.243 0.011 0.949  
DBP −0.111 0.527   0.238 0.169  
FPG −0.107 0.540   −0.126 0.470  
HbA1c 0.165 0.344   0.863 <0.001 0.266
LDL-C 0.063 0.732   0.399 0.024 0.490
TG −0.145 0.427   0.370 0.037 0.420
HDL-C −0.035 0.850   −0.360 0.043 0.537
AST 0.331 0.069   0.218 0.240  
ALT 0.477 0.004 0.543 0.393 0.022 0.418
sCPR 0.050 0.822   0.256 0.239  
Insulin dose 0.105 0.555   0.023 0.897  
Insulin dose U/kg 0.015 0.933   −0.064 0.718  
Eating behavior 0.808 0.003 0.824 0.525 0.098 0.400
Previous treatment
Insulin 0.214 0.217   −0.344 0.043 0.545
BG 0.017 0.921   −0.165 0.343  
SU −0.190 0.273   −0.297 0.083 0.648
αGI −0.054 0.757   −0.026 0.881  
TZD −0.049 0.784   0.083 0.635  
DPP4i 0.031 0.861   −0.127 0.466  
Glinide −0.036 0.836   −0.002 0.992  
  1. Reduction of body weight or HbA1c from baseline to 1 year was analyzed with baseline clinical parameters in 35 subjects whose anti-diabetic agents were not altered except dosage of liraglutide.
  2. BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose, HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerides, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase, ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.